Dec 11, 2021CompletedNCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple MyelomaNCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma This is a Phase 1, open-label study to ...